000118631 001__ 118631
000118631 005__ 20230519145536.0
000118631 0247_ $$2doi$$a10.3390/life11070617
000118631 0248_ $$2sideral$$a126878
000118631 037__ $$aART-2021-126878
000118631 041__ $$aeng
000118631 100__ $$aMarron S.E.
000118631 245__ $$aPatient reported outcome measure in atopic dermatitis patients treated with dupilumab: 52-weeks results
000118631 260__ $$c2021
000118631 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118631 5203_ $$aDupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks 16, 40 and 52. The variables evaluated were: disease severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between 14 Nov 2017 and 16 Jan 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD = 17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD median (range) score = 69.2 (34.8–89.2); itch was reported by 100% of patients; itch visual analogue scale median (range) was 9 (6–10); HADS median (range) total score = 13 (5–21); DLQI mean score = 16 (2–27); EQ-5D-3L median (range) = 57 (30–99). At week- 52 there was a significant reduction of SCORAD scores median (range) = 4.3 (0–17.1), HADS total score median (range) = 2 (0–10) and improved quality of life EQ-5D-3L median (range) = 89 (92–60). This study confirms that dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week 16, with a good safety profile. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000118631 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118631 590__ $$a3.253$$b2021
000118631 591__ $$aBIOLOGY$$b39 / 94 = 0.415$$c2021$$dQ2$$eT2
000118631 592__ $$a0.588$$b2021
000118631 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2021$$dQ2
000118631 593__ $$aSpace and Planetary Science$$c2021$$dQ2
000118631 593__ $$aEcology, Evolution, Behavior and Systematics$$c2021$$dQ2
000118631 594__ $$a1.9$$b2021
000118631 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118631 700__ $$0(orcid)0000-0003-1917-6906$$aTomás Aragonés, L.$$uUniversidad de Zaragoza
000118631 700__ $$aMoncin-torres C.A.
000118631 700__ $$aGomez-barrera M.
000118631 700__ $$ade Aranibar F.J.G.-L.
000118631 7102_ $$14009$$2735$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicolog.Evolut.Educac
000118631 773__ $$g11, 7 (2021), 617 [14 pp]$$pLife (Basel)$$tLife$$x2075-1729
000118631 8564_ $$s2221230$$uhttps://zaguan.unizar.es/record/118631/files/texto_completo.pdf$$yVersión publicada
000118631 8564_ $$s2679254$$uhttps://zaguan.unizar.es/record/118631/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118631 909CO $$ooai:zaguan.unizar.es:118631$$particulos$$pdriver
000118631 951__ $$a2023-05-18-15:35:51
000118631 980__ $$aARTICLE